Colonial Trust Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Colonial Trust Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.3K	Hold	61	–	–	﹤0.01%	402
2026 Q1	$47.4K	Buy	61 +11	+22%	+$8.42K	﹤0.01%	355
2025 Q4	$38.8K	Hold	50	–	–	﹤0.01%	374
2025 Q3	$28.2K	Hold	50	–	–	﹤0.01%	400
2025 Q2	$26.3K	Hold	50	–	–	﹤0.01%	413
2025 Q1	$31.8K	Buy	+50	New	+$34.4K	﹤0.01%	388
2024 Q2	–	Sell	-4	Closed	-$3.85K	–	963
2024 Q1	$3.85K	Sell	4 -5	-56%	-$4.75K	﹤0.01%	733
2023 Q4	$7.91K	Buy	9 +3	+50%	+$2.47K	﹤0.01%	536
2023 Q3	$4.94K	Hold	6	–	–	﹤0.01%	609
2023 Q2	$4.31K	Hold	6	–	–	﹤0.01%	657
2023 Q1	$4.93K	Hold	6	–	–	﹤0.01%	621
2022 Q4	$4.33K	Buy	+6	New	+$4.43K	﹤0.01%	640

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Colonial Trust Advisors's REGN Position: Q2 2026 in Review

Colonial Trust Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 61 shares worth $38.3K. The position accounts for ﹤0.01% of the portfolio, ranked #402.

Colonial Trust Advisors first reported a position in REGN in Q4 2022 and has held it in 12 quarters since. The position peaked at $47.4K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Colonial Trust Advisors held 61 shares of Regeneron Pharmaceuticals worth $38.3K as of Q2 2026.
Colonial Trust Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q2 2026, its #402 holding.
Colonial Trust Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
Colonial Trust Advisors's Regeneron Pharmaceuticals position peaked at $47.4K in Q1 2026.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Colonial Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.